Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1b/2 Double-Blind Randomized Trial in Extensive-Stage Small Cell Lung Cancer
2012-003174-83Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Eli Lilly and Company. Primary endpoint: Safe and tolerable Phase 2 dose determination. Started Oct 2012; status: terminated.
02
Drugs
carboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2012-003174-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003174-83.